HomeCompareNEW vs MRK

NEW vs MRK: Dividend Comparison 2026

NEW yields 147.06% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NEW wins by $22.54M in total portfolio value
10 years
NEW
NEW
● Live price
147.06%
Share price
$1.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.60M
Annual income
$9,667,205.19
Full NEW calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — NEW vs MRK

📍 NEW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNEWMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NEW + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NEW pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NEW
Annual income on $10K today (after 15% tax)
$12,500.00/yr
After 10yr DRIP, annual income (after tax)
$8,217,124.41/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, NEW beats the other by $8,208,527.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NEW + MRK for your $10,000?

NEW: 50%MRK: 50%
100% MRK50/50100% NEW
Portfolio after 10yr
$11.33M
Annual income
$4,838,659.48/yr
Blended yield
42.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NEW
Analyst Ratings
1
Buy
Consensus: Buy
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NEW buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNEWMRK
Forward yield147.06%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$22.60M$57.7K
Annual income after 10y$9,667,205.19$10,113.78
Total dividends collected$20.88M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: NEW vs MRK ($10,000, DRIP)

YearNEW PortfolioNEW Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$25,406$14,705.88$11,213$373.04+$14.2KNEW
2$62,102$34,917.38$12,667$512.06+$49.4KNEW
3$146,216$79,767.65$14,439$708.14+$131.8KNEW
4$331,975$175,523.78$16,640$988.16+$315.3KNEW
5$727,658$372,444.73$19,432$1,394.07+$708.2KNEW
6$1,541,551$762,956.42$23,057$1,992.90+$1.52MNEW
7$3,160,048$1,510,588.88$27,889$2,894.79+$3.13MNEW
8$6,275,251$2,893,998.93$34,518$4,286.29+$6.24MNEW
9$12,085,478$5,370,960.29$43,912$6,494.35+$12.04MNEW
10$22,598,667$9,667,205.19$57,714$10,113.78+$22.54MNEW

NEW vs MRK: Complete Analysis 2026

NEWStock

Puxin Limited, together with its subsidiaries, provides K-12 and study-abroad tutoring services in the People's Republic of China. Its K-12 tutoring services offer result-oriented educational services in various forms, such as classroom-based after-school tutoring, full-time tutoring for preparation of university entrance exams, and art college admission exams, as well as online courses in a large-class setting to help students enhance their academic results through group class and personalized tutoring courses; full-time tutoring services to high school students preparing for university entrance exams and art college admission exams; after-school tutoring services in group class settings and through personalized sessions; personalized K-12 tutoring courses to adapt to each student's learning pace, pattern, and approach; and extracurricular courses, such as painting, calligraphy, and science. The company's study-abroad tutoring services helps students to prepare for admission tests and applications for high schools, universities, and graduate programs primarily in English-speaking countries through study-abroad test preparation courses and study-abroad consulting services. It also provides web-based platforms and mobile apps for K-12 tutoring services; and cloud-based products and services for K-12 tutoring and study-abroad tutoring services. As of December 31, 2020, it operated 407 learning centers, which include 328 K-12 and 79 study-abroad learning centers. The company offers its products under the Puxin, Puxin-Lingxian, Puxin-YESSAT, Puxin-Fubusi, and ZMN Education brands, as well as operates franchised schools under the Global Education brand. Puxin Limited was founded in 2014 and is headquartered in Beijing, the People's Republic of China.

Full NEW Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NEW vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NEW vs SCHDNEW vs JEPINEW vs ONEW vs KONEW vs MAINNEW vs JNJNEW vs ABBVNEW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.